See more : Yoong Onn Corporation Berhad (5159.KL) Income Statement Analysis – Financial Results
Complete financial analysis of SpringWorks Therapeutics, Inc. (SWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SpringWorks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aquarius AI Inc. (AQUA.CN) Income Statement Analysis – Financial Results
- Nordic Paper Holding AB (publ) (NPAPER.ST) Income Statement Analysis – Financial Results
- DMK Pharmaceuticals Corporation (0A4X.L) Income Statement Analysis – Financial Results
- TI Cloud Inc. (2167.HK) Income Statement Analysis – Financial Results
- Nichias Corporation (5393.T) Income Statement Analysis – Financial Results
SpringWorks Therapeutics, Inc. (SWTX)
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.45M | 6.15M | 0.00 | 35.00M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 422.00K | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| Gross Profit | 5.03M | 4.25M | -490.00K | 34.65M | -192.00K | -17.33K | -3.18K |
| Gross Profit Ratio | 92.25% | 69.16% | 0.00% | 99.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 150.49M | 146.12M | 101.68M | 51.86M | 42.55M | 9.90M | 2.80M |
| General & Administrative | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 5.58M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.73M |
| SG&A | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 1.86M |
| Other Expenses | 0.00 | -138.00K | -152.00K | 25.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 348.04M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Cost & Expenses | 348.46M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Interest Income | 22.95M | 6.15M | 698.00K | 1.33M | 3.55M | 678.00K | 63.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.67M | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| EBITDA | -341.35M | -280.67M | -172.98M | -45.98M | -59.05M | -18.47M | -4.64M |
| EBITDA Ratio | -6,266.68% | -4,566.03% | 0.00% | -131.36% | 0.00% | 0.00% | 0.00% |
| Operating Income | -343.01M | -280.67M | -173.47M | -46.32M | -59.24M | -18.49M | -4.66M |
| Operating Income Ratio | -6,297.28% | -4,566.03% | 0.00% | -132.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.91M | 3.26M | -442.00K | 750.00K | 933.00K | 678.00K | 21.00K |
| Income Before Tax | -325.10M | -277.42M | -173.91M | -45.57M | -58.31M | -17.81M | -4.64M |
| Income Before Tax Ratio | -5,968.50% | -4,513.05% | 0.00% | -130.21% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.26M | -698.00K | -1.33M | -3.55M | 678.00K | -2.00 |
| Net Income | -325.10M | -274.16M | -173.21M | -44.24M | -54.76M | -17.81M | -4.64M |
| Net Income Ratio | -5,968.50% | -4,460.06% | 0.00% | -126.41% | 0.00% | 0.00% | 0.00% |
| EPS | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| EPS Diluted | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| Weighted Avg Shares Out | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
| Weighted Avg Shares Out (Dil) | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
SpringWorks Therapeutics (SWTX) Reports Q2 Loss, Tops Revenue Estimates
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Source: https://incomestatements.info
Category: Stock Reports